Capricor Therapeutics to Present at the 2018 BIO International Convention in Boston
May 29 2018 - 7:00AM
Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company
developing biological therapies for Duchenne muscular dystrophy and
other rare disorders, today announced that Linda Marbán, Ph.D., its
president and chief executive officer, is scheduled to provide a
corporate update at the 2018 BIO International Convention on
Monday, June 4.
2018 BIO International Convention
Date of presentation: Monday, June
4, 2018 Time: 4:45 p.m. to 5 p.m. ET
Location: Theater 2, Boston Convention & Exhibition
Center
To participate via a webcast, please visit:
http://www.veracast.com/webcasts/bio/internationalconvention2018/65114254741.cfm
The webcast will be archived for approximately
30 days and will be available at
http://capricor.com/news/events/.
About Capricor Therapeutics
Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a
clinical-stage biotechnology company focused on the discovery,
development and commercialization of first-in-class biological
therapeutics for the treatment of rare disorders. Capricor’s lead
candidate, CAP-1002, is an allogeneic cell therapy that is
currently in clinical development for the treatment of Duchenne
muscular dystrophy. Capricor has also established itself as one of
the leading companies investigating the field of extracellular
vesicles and is exploring the potential of CAP-2003, a cell-free,
exosome-based candidate, to treat a variety of disorders. For more
information, visit www.capricor.com.
Keep up with Capricor on social media:
www.facebook.com/capricortherapeutics,
www.instagram.com/capricortherapeutics/ and
https://twitter.com/capricor
About BIO International Convention
The BIO International Convention is hosted by
the Biotechnology Innovation Organization (BIO). BIO represents
more than 1,100 biotechnology companies, academic institutions,
state biotechnology centers and related organizations across the
United States and in more than 30 other nations. BIO members are
involved in the research and development of innovative healthcare,
agricultural, industrial and environmental biotechnology products.
For more information, visit http://convention.bio.org/.
Cautionary Note Regarding Forward-Looking
Statements
Statements in this press release regarding the efficacy, safety,
and intended utilization of Capricor's product candidates; the
initiation, conduct, size, timing and results of discovery efforts
and clinical trials; the pace of enrollment of clinical trials;
plans regarding regulatory filings, future research and clinical
trials; regulatory developments involving products, including the
ability to obtain regulatory approvals or otherwise bring products
to market; plans regarding current and future collaborative
activities and the ownership of commercial rights; scope, duration,
validity and enforceability of intellectual property rights; future
royalty streams, expectations with respect to the expected use of
proceeds from the recently completed offerings and the anticipated
effects of the offerings, and any other statements about Capricor's
management team's future expectations, beliefs, goals, plans or
prospects constitute forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. Any
statements that are not statements of historical fact (including
statements containing the words "believes," "plans," "could,"
"anticipates," "expects," "estimates," "should," "target," "will,"
"would" and similar expressions) should also be considered to be
forward-looking statements. There are a number of important factors
that could cause actual results or events to differ materially from
those indicated by such forward-looking statements. More
information about these and other risks that may impact Capricor's
business is set forth in Capricor's Annual Report on Form 10-K for
the year ended December 31, 2017 as filed with the Securities and
Exchange Commission on March 22, 2018, in its Registration
Statement on Form S-3, as filed with the Securities and Exchange
Commission on September 28, 2015, together with the prospectus
included therein and prospectus supplements thereto and in its
Quarterly Report on Form 10-Q for the quarter ended March 31, 2018,
as filed with the Securities and Exchange Commission on May 14,
2018. All forward-looking statements in this press release are
based on information available to Capricor as of the date hereof,
and Capricor assumes no obligation to update these forward-looking
statements.
CAP-1002 is an Investigational New Drug and is
not approved for any indications. CAP-2003 has not yet been
approved for clinical investigation.
For more information, please contact:
AJ Bergmann, Chief Financial Officer
+1-310-358-3200
abergmann@capricor.com
Capricor Therapeutics (NASDAQ:CAPR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Capricor Therapeutics (NASDAQ:CAPR)
Historical Stock Chart
From Sep 2023 to Sep 2024